iwMyeloma 2017 | Novel therapeutics in multiple myeloma
There are currently many exciting novel therapeutics and combination therapies undergoing clinical trials for use in multiple myeloma (MM) patients. These are explored in an intriguing panel discussion by Thomas Martin, MD from UCSF School of Medicine, San Francisco, CA, Larry Boise, PhD from Emory University School of Medicine, Atlanta, GA, Christoph Driessen, MD, PhD from Kantonsspital St. Gallen, St. Gallen, Switzerland and Constantine Mitsiades, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA at the Myeloma 2017 meeting in Edinburgh, UK. These therapeutics target an array of promising genes, pathways, super-enhancers and transcription factors. The panel reference venetoclax, nelfinavir, dexamethasone and bortezomib combinations in clinical trials for MM, as well as their mechanisms of action and hence why they target different subgroups of patients.
